The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.
The nucleocapsid (HBcAg) of the hepatitis B virus (HBV) has been suggested as a carrier moiety for vaccine purposes. We investigated the influence of the position of the inserted epitope within hybrid HBcAg particles on antigenicity and immunogenicity. For this purpose, genes coding for neutralizing epitopes of the pre-S region of the HBV envelope proteins were inserted at the amino terminus, the amino terminus through a precore linker sequence, the truncated carboxy terminus, or an internal site of HBcAg by genetic engineering and were expressed in Escherichia coli. All purified hybrid HBc/pre-S polyproteins were particulate. Amino- and carboxy-terminal-modified hybrid HBc particles retained HBcAg antigenicity and immunogenicity. In contrast, insertion of a pre-S(1) sequence between HBcAg residues 75 and 83 abrogated recognition of HBcAg by 5 of 6 anti-HBc monoclonal antibodies and diminished recognition by human polyclonal anti-HBc. Predictably, HBcAg-specific immunogenicity was also reduced. With respect to the inserted epitopes, a pre-S(1) epitope linked to the amino terminus of HBcAg was not surface accessible and not immunogenic. A pre-S(1) epitope fused to the amino terminus through a precore linker sequence was surface accessible and highly immunogenic. A carboxy-terminal-fused pre-S(2) sequence was also surface accessible but weakly immunogenic. Insertion of a pre-S(1) epitope at the internal site resulted in the most efficient anti-pre-S(1) antibody response. Furthermore, immunization with hybrid HBc/pre-S particles exclusively primed T-helper cells specific for HBcAg and not the inserted epitope. These results indicate that the position of the inserted B-cell epitope within HBcAg is critical to its immunogenicity.
Schödel
F
F
Max-Planck-Institut für Biochemie, Martinsried, Germany.
Moriarty
A M
AM
Peterson
D L
DL
Zheng
J A
JA
Hughes
J L
JL
Will
H
H
Leturcq
D J
DJ
McGee
J S
JS
Milich
D R
DR
D000818:Animals; D001483:Base Sequence; D003001:Cloning, Molecular; D004279:DNA, Viral; D000939:Epitopes; D005260:Female; D006510:Hepatitis B Antibodies / Q000276:immunology; D006512:Hepatitis B Core Antigens / Q000235:genetics / Q000276:immunology* / Q000648:ultrastructure; D006514:Hepatitis B Surface Antigens / Q000235:genetics / Q000276:immunology / Q000648:ultrastructure; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology* / Q000648:ultrastructure; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008854:Microscopy, Electron; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D011498:Protein Precursors / Q000235:genetics / Q000276:immunology / Q000648:ultrastructure; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000648:ultrastructure; D013601:T-Lymphocytes / Q000276:immunology; D014758:Viral Core Proteins / Q000235:genetics / Q000276:immunology*
D004279:DNA, Viral; D000939:Epitopes; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D011498:Protein Precursors; D011993:Recombinant Fusion Proteins; D014758:Viral Core Proteins; C050806:presurface protein 1, hepatitis B surface antigen; C050807:presurface protein 2, hepatitis B surface antigen